875877-40-0

Upstream product

• 313273-69-7 8-bromo-3-methyl-7-(3-methyl-but-2-enyl)-3,7-dihydro-purine-2,6-dione 
• 70-11-1 α-bromoacetophenone 

Downstream Products

• 876134-85-9 8-(2-amino-1,1-dimethyl-ethylsulfanyl)-3-methyl-7-(3-methyl-but-2-enyl)-1-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purin-2,6-dione 
• 876136-30-0 8-mercapto-3-methyl-7-(3-methyl-but-2-enyl)-1-(2-oxo-2-phenyl-ethyl)-3,7-dihydro-purin-2,6-dione 
• 454710-78-2 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-[3-(tert.-butyloxycarbonylamino)-piperidin-1-yl]-xanthine 
• 1443216-76-9 C₂₆H₃₂N₆O₃ 
• 1443216-54-3 C₃₁H₄₀N₆O₅ 
• 1443216-74-7 C₂₇H₃₅N₅O₆ 
• 1443216-73-6 C₂₈H₃₇N₅O₆ 
• 1443216-71-4 C₂₇H₃₅N₅O₆ 
• 1443216-72-5 C₂₉H₃₉N₅O₆ 

Relevant academic research and scientific papers

8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin- 2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes

A new chemical class of potent DPP-4 inhibitors structurally derived from the xanthine scaffold for the treatment of type 2 diabetes has been discovered and evaluated. Systematic structural variations have led to 1 (BI 1356), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species. 1 is currently undergoing clinical phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.

SUBSTITUTED 8-AMINOALKYLTHIOXANTHINES, AND THEIR USE AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV

The invention 8-aminothioxanthines and the derivatives of formula I wherein the various R groups and substituents are comprised of a number of different (C1-C10)-alkyl, cycloalkyl, aryl, alkene, alkyne, etc. groups and derivatives thereof which are hereinafter more specifically defined for the treatment of metabolic disorders such as type-2 diabetes, hyperglycemia, arteriosclerotic diseases and the like

SUBSTITUTED 8-AMINOALKYLTHIO-XANTHINES, AND THE USE THEREOF AS INHIBITORS OF THE DIPEPTIDYL PEPTIDASE IV

The invention relates to substituted 8-aminoalkylthio-xanthines, to the physiologically compatible salts thereof and to the physiologically functional derivatives thereof. The invention also relates to compounds of formula (I), wherein the groups have the meaning cited in the description, in addition to the physiologically compatible salts thereof. The compounds can be used, for example, as medicaments for the prevention and treatment of type 2 diabetes.

SUBSTITUTED 8-AMINOALKOXI-XANTHINES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS

The invention relates to substituted 8-aminoalkoxi-xanthines and to the physiologically compatible salts thereof and physiologically functional derivatives. The invention also relates to compounds of formula (I), wherein the radicals have the above-mentioned meaning, in addition to the physiologically compatible salts thereof. The compounds are suitable, for example, as medicaments for the prevention and treatment of type 2 diabetes.